# A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

> **NCT04350463** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 92 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** CC-90011
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04350463
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-14
- **Primary completion:** 2023-12-19
- **Final completion:** 2023-12-19
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2025-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04350463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04350463, "A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04350463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*